News
VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients
Vakzine Projekt Management GmbH (VPM) announced today that it has supported Memo Therapeutics AG (MTx) during the process for receiving fast track designation from the U.S. Food and Drug Administration (FDA) for the novel human monoclonal antibody, AntiBKV, developed by MTx for the treatment of BK viremia in kidney transplant recipients. READ MORE
VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana
Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the novel R21/Matrix-MTMÂ Malaria Vaccine by the Ghana Food and Drugs Authority (FDA) for use in children as young as 5 months old up to 36 months old, in Ghana. This approval is an exciting milestone and was achieved by the joint global efforts of VPM, Serum Institute of India (SII), Oxford University, and DEK Vaccines Ltd (DEK). This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa READ MORE
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
We are pleased to announce the successful completion of a clinical client project for Memo Therapeutics AG (MTx), Switzerland. The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients. VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met. Click here for more information.
Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases
The course of respiratory infectious disease pandemics, will strongly depend on how quickly medications or specific vaccines against the pathogens are available. Researchers wanted to investigate in a phase III trial whether the vaccine candidate VPM1002 is also protective against an infection with the novel SARS-CoV-2. The large-scale study has been carried out at several hospitals in Germany and included older people that are susceptible to severe course of the disease. Read about the results here!
VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly
We are pleased to announce that our VPM1002 trial, where VPM1002 was given as a prophylaxis against severe respiratory infectious diseases including COVID-19 in the elderly, has successfully been published in the journal Clinical Infectious Diseases. We could show that VPM1002 compared to placebo is reducing the days with severe respiratory disease! Read more!
VPM celebrated its 20 year anniversary during the joint symposium organized by TWINCORE and VPM.
We are very proud to be able to welcome more than 100 participants at TWINCORE in Hannover!. Read more.
Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau
An article about our tuberculosis (TB) vaccine has been published in the “Frankfurter Rundschau”. For more info click here.
Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows
A clinical trial in South Africa has now shown that the new vaccine candidate VPM1002, developed by Max Planck researcher Stefan H.E. Kaufmann and his team, is equally safe for newborns with and without HIV exposure and has fewer side effects compared to BCG. Please click here to read the publication.
Milestone achieved: end of recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.
VPM at the OPTIMMUNIZE 2022 Meeting
VPM was invited guest speaker at the OPTIMMUNIZE 2022 which was held as webinar on April 21st. Watch the video here!